The treatment landscape for multiple myeloma has undergone a dramatic transformation over the past decade, driven by a growing arsenal of immunotherapies that harness the patient’s own immune system to fight cancer. Now, results from a large international Phase III trial suggest that one of the newest entrants to this class, the bispecific antibody teclistamab, may be poised to move even earlier in the treatment paradigm.
The findings, published in the New England Journal of Medicine and presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, showed that teclistamab significantly improved progression-free survival and depth of response compared with standard therapies in patients with relapsed multiple myeloma.
The study represents one of the strongest demonstrations to date that chemotherapy-free immunotherapy can outperform conventional approaches even after only a limited number of prior treatments.
Moving bispecific antibodies earlier in treatment
Teclistamab belongs to a rapidly expanding class of therapies known as bispecific antibodies. Unlike traditional monoclonal antibodies, bispecifics are engineered to bind two targets simultaneously. Teclistamab recognizes both BCMA, a protein expressed on multiple myeloma cells, and CD3 on T cells, effectively bringing immune cells into direct contact with tumor cells and triggering targeted cancer cell killing.
The therapy has already shown substantial activity in heavily pretreated patients with advanced disease. However, investigators wanted to determine whether moving the drug earlier in the disease course could provide even greater benefit.
“Now we have chemotherapy-free immunotherapy options for patients whose myeloma has relapsed for the first time,” said C. Ola Landgren, MD, chief of the Sylvester Myeloma Institute and senior author of the study. “We are seeing very deep responses and long clinical benefit from these therapies. This is part of a much bigger transformation happening in myeloma care.”
Landmark global trial
The Phase III MajesTEC-9 trial enrolled 593 patients across 24 countries. Participants had relapsed multiple myeloma after one to three prior lines of therapy, representing a patient population increasingly encountered in routine clinical practice.
Approximately three-quarters of patients had already become refractory to commonly used treatments, including immunomodulatory drugs such as lenalidomide and anti-CD38 therapies such as daratumumab. These patients typically face diminishing treatment options and shorter durations of disease control.
Patients were randomized to receive either teclistamab or standard treatment regimens.
The results demonstrated a clear advantage for the bispecific antibody.
After 18 months of follow-up, nearly 70% of patients treated with teclistamab remained free from disease progression, compared with only about 27% of patients receiving standard therapies.
The magnitude of benefit exceeded what many clinicians have come to expect in relapsed myeloma, where treatment resistance often emerges rapidly.
Deep remissions become increasingly common
Beyond delaying disease progression, teclistamab produced remarkably deep responses.
Nearly two-thirds of treated patients achieved complete remission, meaning no evidence of disease could be detected using conventional testing methods.
Another highlight was the frequency of minimal residual disease (MRD) negativity, an increasingly important endpoint in multiple myeloma research. MRD testing uses highly sensitive techniques capable of detecting tiny numbers of remaining cancer cells that standard assessments might miss.
Many patients receiving teclistamab achieved MRD-negative status, suggesting that the therapy may be capable of driving deep eradication of disease.
“To see that this drug is so efficacious and so safe across patients from all these locations worldwide is a very strong signal,” Landgren said. “To see that in patients who have been exposed and refractory to commonly used myeloma treatments is very important.”
The broader shift away from chemotherapy
The results reflect a larger evolution occurring throughout multiple myeloma treatment.
For decades, chemotherapy served as the backbone of therapy. Today, however, treatment increasingly revolves around immune-based approaches including monoclonal antibodies, CAR T-cell therapies, and bispecific antibodies.
Researchers are not only developing new immunotherapies but also moving them earlier into treatment algorithms, where the immune system may be more intact and capable of mounting stronger anti-tumor responses.
The success of teclistamab in earlier-relapse patients supports this strategy and raises the possibility that bispecific antibodies could eventually become standard components of frontline treatment.
Managing infection risk remains critical
Despite the encouraging efficacy results, teclistamab is not without challenges.
Because the therapy activates T cells and alters immune function, infection remains one of the most important safety considerations. The risk is particularly pronounced during the first several months of treatment, when immune suppression can occur as part of the therapeutic response.
To mitigate this risk, patients typically receive antiviral and antibiotic prophylaxis, undergo routine monitoring of immunoglobulin levels, and may receive supplemental immunoglobulin infusions when necessary.
Investigators reported that these risks were manageable with appropriate monitoring and supportive care, consistent with previous studies of bispecific antibodies.
Looking toward curative strategies
The success of teclistamab is part of a broader effort to transform multiple myeloma from a chronic relapsing disease into one that can potentially be controlled for extended periods, or perhaps one day cured.
Researchers are already investigating whether teclistamab and related bispecific antibodies can be incorporated into even earlier treatment settings, including newly diagnosed disease.
“For me, the goal is to develop curative strategies,” Landgren said. “We are working toward treatments that can either eliminate the disease entirely or control it for very long periods while minimizing the burden on patients and preserving quality of life.”
As bispecific antibodies continue to demonstrate increasingly durable responses, the field is moving closer to that goal. The MajesTEC-9 results suggest that immune-based therapies are no longer merely alternatives to conventional treatment, they may be emerging as the new standard for many patients with relapsed multiple myeloma.
The post Teclistamab Outperforms Standard Therapy in Relapsed Multiple Myeloma appeared first on Inside Precision Medicine.
